Personalis Announces Podium Presentations and Abstracts Accepted at ASCO 2024

Rhea-AI Summary

Personalis announced that two podium presentations and multiple posters featuring its NeXT Personal® ctDNA assay will be showcased at the 2024 ASCO Annual Meeting, set for May 31-June 4 in Chicago. The presentations include studies on ctDNA's role in breast cancer and immunotherapy biomarkers. Dr. Richard Chen highlighted the importance of their ultra-sensitive MRD test in early cancer detection. Key presentations will focus on ctDNA mutation tracking in early breast cancer (Abstract 1010) and ctDNA monitoring in metastatic pan-cancer with immune checkpoint inhibitors (Abstract 2510). Additional abstracts discuss ctDNA dynamics in gastroesophageal and colorectal cancers, as well as HER2+ breast cancer.

Positive

• Personalis' NeXT Personal® ctDNA assay will be featured in two podium presentations at ASCO 2024, highlighting its industry recognition.
• The company is involved in forward-looking research, such as the role of ctDNA in early breast cancer and immunotherapy biomarkers.
• Acceptance of multiple abstracts and posters at ASCO emphasizes Personalis' active contributions to clinical oncology research.
• The NeXT Personal® assay's use in high-profile studies may enhance its credibility and adoption in precision oncology.

Negative

• The PR does not mention any immediate financial gains or new partnerships resulting from the ASCO presentations.
• There is no discussion about potential risks or challenges related to the implementation of the NeXT Personal® ctDNA assay in clinical settings.
• The press release lacks concrete data on the assay’s performance, limiting its immediate impact on investor decisions.

FREMONT, Calif.--(BUSINESS WIRE)-- Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that two podium presentations and multiple posters featuring data for the company’s NeXT Personal^® whole genome-based, tumor-informed assay for ultra-sensitive ctDNA detection will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, which convenes from May 31-June 4, 2024, in Chicago, Illinois.

“As the body of studies continues to grow that demonstrates the role our ultra-sensitive MRD test, NeXT Personal, can play in identifying recurrent cancer early, we were honored to learn that two Personalis studies were selected as podium presentations at ASCO 2024’s Clinical Science Symposium”, said Dr. Richard Chen, Chief Medical Officer and Executive Vice President, R&D at Personalis.

The two studies that were selected to appear as podium presentations are:

• Clinical Science Symposium: Emerging Role of ctDNA in Breast Cancer
  • Presenter: Isaac Garcia-Murillas, PhD
  • Overview: Ultra-sensitive ctDNA mutation tracking to identify molecular residual disease and predict relapse in patients with early breast cancer.
  • Abstract Number: 1010
• Clinical Science Symposium: Hitting the Mark - The Ongoing Search for Immunotherapy Biomarkers
  • Presenter: Rodrigo A Toledo, PhD, MBA
  • Overview: Prognostic and predictive value of ultrasensitive ctDNA monitoring in a metastatic pan-cancer cohort treated with immune checkpoint inhibitors in the context of phase 1 clinical trials.
  • Abstract Number: 2510

Details of the Personalis abstracts are outlined below, and further details about the poster presentations can be found here.

• Abstract Title: Emerging Role of ctDNA in Breast Cancer
  • Presenter: Andrew B. Nixon PhD, MBA
  • Overview: Ultra-sensitive ctDNA dynamics to capture therapy response in pembrolizumab-treated gastroesophageal cancer.
  • Abstract Number: 4025
• Abstract Title: Breast Cancer—Local/Regional/Adjuvant
  • Presenter: Adrienne Gropper Waks, MD
  • Overview: Prevalence and dynamics of circulating tumor DNA (ctDNA) among patients (pts) with HER2+ breast cancer (BC) receiving neoadjuvant paclitaxel/trastuzumab/pertuzumab (THP) in the DAPHNe trial.
  • Abstract Number: 588
• Publication Title: Gastrointestinal Cancer—Colorectal and Anal
  • First Author: Joao Paulo Solar Vasconcelos, MD
  • Overview: Circulating tumor DNA (ctDNA) kinetics in colorectal cancer (CRC) treated with curative intent in the VICTORI study with an ultrasensitive MRD assay.
  • Abstract Number: e15625

About Personalis, Inc.

At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care from biopsy through the life of the patient. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect minimal residual disease (MRD) and recurrence at the earliest time points, enable the selection of targeted therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development. Personalis is based in Fremont, California. To learn more, visit www.personalis.com and connect with us on LinkedIn and X (Twitter).

Forward-Looking Statements

All statements in this press release that are not historical are “forward-looking statements” within the meaning of U.S. securities laws, including statements relating to attributes or advantages of the NeXT Personal assay, the potential for NeXT Personal to identify recurrent cancer early, or other future events. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any anticipated results or expectations expressed or implied by such statements. Factors that could materially affect actual results can be found in Personalis’ filings with the U.S. Securities and Exchange Commission, including Personalis’ most recent reports on Forms 8-K, 10-K and 10-Q, and include those listed under the caption “Risk Factors.” Personalis disclaims any obligation to update such forward-looking statements.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240522193620/en/

Investors:

Caroline Corner

investors@personalis.com

415-202-5678

Media:

pr@personalis.com

Source: Personalis, Inc.

FAQ

What is the relevance of Personalis' NeXT Personal® ctDNA assay at ASCO 2024?

The NeXT Personal® ctDNA assay will be showcased in two podium presentations and multiple posters, emphasizing its role in precision oncology.

When and where will Personalis present their studies at ASCO 2024?

Personalis will present at the ASCO Annual Meeting from May 31 to June 4, 2024, in Chicago, Illinois.

What topics will Personalis' ASCO 2024 presentations cover?

The presentations will cover ctDNA mutation tracking in early breast cancer, and ctDNA monitoring in metastatic pan-cancer with immune checkpoint inhibitors.

Who are the presenters for Personalis' ASCO 2024 studies?

Isaac Garcia-Murillas, PhD, and Rodrigo A Toledo, PhD, MBA, will present the podium presentations on ctDNA roles in cancer.

What is the focus of the abstract number 1010 by Personalis at ASCO 2024?

Abstract 1010 focuses on ultra-sensitive ctDNA mutation tracking to identify molecular residual disease in early breast cancer.

What is the significance of abstract number 2510 by Personalis?

Abstract 2510 explores the prognostic and predictive value of ultra-sensitive ctDNA monitoring in a metastatic pan-cancer cohort.